Litcius/Paper detail

Measurable residual disease (MRD) testing for acute leukemia in EBMT transplant centers: a survey on behalf of the ALWP of the EBMT

Arnon Nagler, Frédéric Baron, Myriam Labopin, Emmanuelle Polge, Jordi Esteve, Ali Bazarbachi, Éolia Brissot, Gesine Bug, Fabio Ciceri, Sebastian Giebel, Maria Gilleece, Norbert Claude Gorin, Francesco Lanza, Zinaida Perić, Annalisa Ruggeri, Jaime Sanz, Bipin N. Savani, Christoph Schmid, Roni Shouval, Alexandros Spyridonidis, Jurjen Versluis, Mohamad Mohty

2020Bone Marrow Transplantation43 citationsDOIOpen Access PDF

Topics & Concepts

MedicineMinimal residual diseaseInternal medicineOncologyLeukemiaMyeloid leukemiaTransplantationAcute Myeloid Leukemia ResearchAcute Lymphoblastic Leukemia researchCancer Genomics and Diagnostics
Measurable residual disease (MRD) testing for acute leukemia in EBMT transplant centers: a survey on behalf of the ALWP of the EBMT | Litcius